Last reviewed · How we verify
CombiflexOmega
CombiflexOmega combines multiple mechanisms to modulate inflammatory and metabolic pathways, likely targeting omega-3 fatty acid metabolism and immune regulation.
At a glance
| Generic name | CombiflexOmega |
|---|---|
| Sponsor | JW Life Science |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
The drug name suggests a combination approach leveraging omega-3 polyunsaturated fatty acids with additional active components to address inflammatory conditions. The exact molecular targets and synergistic mechanisms are not publicly detailed in available literature, making the precise mechanism of action unclear at this phase of development.
Approved indications
Common side effects
Key clinical trials
- A Safety, Efficacy Study of CombiflexOmega Peri Versus SmofKabiven Peripheral in Patients With Parenteral Nutrition (PHASE3)
- A Safety, Efficacy Study of CombiflexOmega Versus SmofKabiven in Patients With Parenteral Nutrition (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CombiflexOmega CI brief — competitive landscape report
- CombiflexOmega updates RSS · CI watch RSS
- JW Life Science portfolio CI